Moreover, new mutations have been described that may influence the clinical outcome and the response to therapy with new drugs of GIST, such as BRAF mutation, SDH deficiency, and NF-1 mutant [31–35]. This evidence concerns the gene NF1 and gastrointestinal stromal tumor.